Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

16.30 +0.06 (+0.37%)
Streaming Delayed Price Updated: 10:03 AM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 Next >
Crude Oil Gains 1%; US Composite PMI Surges In March
Via Benzinga
Exposures Fossil Fuels
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday
Via Benzinga
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Where AnaptysBio Stands With Analysts
Via Benzinga
Analyst Expectations For AnaptysBio's Future
Via Benzinga
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Key Takeaways From AnaptysBio Analyst Ratings
Via Benzinga
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts
Via Benzinga
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming trial results in 2025-2026. 
Via Benzinga
What Analysts Are Saying About AnaptysBio Stock
Via Benzinga
Insiders Buying Yum China And 2 Other Stocks
Via Benzinga
4 Analysts Assess AnaptysBio: What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why AnaptysBio Was Such a Healthy Stock This Week
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor. 
Via The Motley Fool
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis. 
Via Investor's Business Daily
S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday
US inflation eases in July, keeping Fed rate cut hopes alive. Stocks rise, yields stable, dollar gains against yen. Tech and small caps outperform. 
Via Benzinga
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.